Navigation Links
BioMS Medical announces first quarter 2008 results
Date:5/15/2008

million to corporate administrative personnel; costs associated with the completion of the licensing agreement including travel, consultants, legal advisors and financials advisors; and increased investor relations and media relations costs in support of creating awareness for BioMS in the US and Canada.

Investment income earned on funds invested was $0.7 million for the three months ended March 31, 2008, compared to $0.4 million for the first three months of the previous year.

At March 31, 2008, cash and short-term investments totaled $107.9 million as compared to $38.0 million at December 31, 2007. At March 31, 2008, the Company had working capital of $105.0 million (excluding the current portion of deferred revenue which does not represent a cash obligation) as compared to $34.8 million at December 31, 2007. Management estimates that the current working capital is sufficient for the Company to meet its obligations in respect of the currently initiated clinical trials for which it is responsible under the Lilly agreement.

As at March 31, 2008 there were 91,400,523 common shares of the Company issued and outstanding, 26,021,528 warrants and 9,001,000 stock options.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to MBP8298 in exchange for an US $87 million upfront payment, mileston
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... July 27, 2015 , ... Production of high tenacity filament yarn ... years in the EU. For instance, it surpassed the EUR 106 million mark (in ... in 2010. Germany is a major producer, while Italy is a key consumer. ...
(Date:7/27/2015)... According to the new Market Research ... Media), by Application (Biobanking, Regenerative Medicine, Drug Discovery), by Geography ... , Asia-Pacific , Rest of the World) ... market was valued at $247.7 million in 2014, which is ... a CAGR of 18.2% between 2014 and 2019. ...
(Date:7/26/2015)... ... July 26, 2015 , ... ... VALIDATE® ANEMIA calibration verification / linearity test kit. The VALIDATE® ANEMIA kit contains ... ANEMIA kit is prepared using the CLSI recommended “equal delta” method for linearity ...
(Date:7/24/2015)... , July 24, 2015  Champions Oncology (OTC-BB: ... technology solutions and services to personalize the development and ... its financial and operational results for the fourth quarter ... Tuesday, July 28, 2015, before market open. ... the results that day at 9:00 a.m. EDT (6:00 ...
Breaking Biology Technology:High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2Champions Oncology to Announce Fourth Quarter Financial Results on Tuesday, July 28 2
... LLC (, http://www.CJPS-Enterprises.com ) announced that it ... services to leverage companies, intellectual property (IP) to ... of their intangible assets.,This customized service is execution-driven, ... a firm that specializes in growing,companies in the ...
... ... Prostate Surgery, SAN DIEGO, Nov. ... InnerCool Therapies, Inc., today,announced that it has developed a pelvic cooling ... surgery,for prostate cancer (radical prostatectomy). The new technology is being,applied in ...
... Vitamin E May Help,Prevent, Cardiovascular Events in Hp2-2 ... (Amex: SYI ) today announced new data demonstrating ... Diabetes may result,in an increased risk of heart attack ... today at the Annual Scientific,Sessions of the American Heart ...
Cached Biology Technology:CJPS Enterprises Provides New Strategies To Create Additional Revenues for Companies with Intellectual Property 2Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 2Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 3Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 4Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 5Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 6Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 7Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 8Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting 2Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting 3Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting 4
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... the addition of the "Next Generation Biometrics Market ... to 2020" report to their offering. ... $24.4 Billion by 2020, at a CAGR of 17.9% ... is the leading application for the market. Safran ...
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/25/2015)... DALLAS , June 25, 2015 ... report "Fingerprint Sensors Market by Type (Swipe & Area), Technology, ... (Mobile, Government, Healthcare, Commercial Security & Others) & ... published by marketsandmarkets, the said market is expected ... CAGR of 17.1%. Browse 76 ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... Mount Sinai School of Medicine have found in a ... Mount Sinai stabilized or improved cardiac function in people ... of the therapy, called SERCA2a, experienced substantial clinical benefit ... need in this population. The data are published online ...
... Some areas of the southern United States are suffering from ... University study shows that could prove problematic for aquatic organisms. ... some chemicals in the environment more toxic to fish and ... exacerbate the magnitudes of the natural pH shifts in the ...
... seawater algae could hold the key to crops as a ... climates. Researchers at the University of Edinburgh have found ... its main food source is in short supply. Understanding ... when nutrients are scarce and to grow high-yield plants for ...
Cached Biology News:Mount Sinai researchers develop new gene therapy for heart failure 2Study shows climate change makes some chemicals more toxic to aquatic life 2
... system, 100-120 V, is used for biolistic ... handheld device employs an adjustable helium pulse ... gold microcarriers from the inner wall of ... cells. This system has a 2 square-centimeter ...
... Clean and Accurate Results Laser Capture ... the sensitivity and accuracy of molecular assays ... types and multi-cellular structures isolated from whole ... to microdissection-developed in 1996 at the National ...
...
Mouse monoclonal antibody raised against a partial recombinant DHX8. NCBI Entrez Gene ID = DHX8...
Biology Products: